FORMULATION AND DEVELOPMENT OF LENALIDOMIDE LOADED DELAYED RELEASE MINI TABLETS IN CAPSULES

L. Sonali Mehta; D. V. Gowda; N. Vishal Gupta; Manohar M.

doi:10.22159/ijap.2018v10i5.26658

Authors

L. Sonali Mehta Department of Pharmaceutics, JSS College of Pharmacy, Sri Shivarathreeshwara Nagara, Mysuru, JSS Academy of Higher Education and Research, JSS Medical Institutions Campus, Sri Shivarathreeshwara Nagara, Mysuru 570015, Karnataka, India
D. V. Gowda Department of Pharmaceutics, JSS College of Pharmacy, Sri Shivarathreeshwara Nagara, Mysuru, JSS Academy of Higher Education and Research, JSS Medical Institutions Campus, Sri Shivarathreeshwara Nagara, Mysuru 570015, Karnataka, India
N. Vishal Gupta Department of Pharmaceutics, JSS College of Pharmacy, Sri Shivarathreeshwara Nagara, Mysuru, JSS Academy of Higher Education and Research, JSS Medical Institutions Campus, Sri Shivarathreeshwara Nagara, Mysuru 570015, Karnataka, India
Manohar M. Department of Pharmaceutics, JSS College of Pharmacy, Sri Shivarathreeshwara Nagara, Mysuru, JSS Academy of Higher Education and Research, JSS Medical Institutions Campus, Sri Shivarathreeshwara Nagara, Mysuru 570015, Karnataka, India

DOI:

https://doi.org/10.22159/ijap.2018v10i5.26658

Keywords:

Immuno-modulator, Mini-tablets, Delayed-release, Tablets in capsule, Lenalidomine

Abstract

Objective: Formulation and development of delayed release mini tablets in the capsule of drug lenalidomidein terms of dissolution and stability was the objective of the present work.

Methods: Tablets of less than or equal to 3 millimetres diameter are Mini-tablets, which were filled into a capsule. Direct compression method using multi-tip punch was used for compression and coated with eudragit L100 as a seal coating material and with eudragit L30D55 as an enteric coating material was done. Different formulations were prepared and subjected for evaluation like weight variation, hardness, friability, disintegration, and dissolution studies. The optimized formulation was compared to marketed product based on drug released profile and also subjected for stability studies.

Results: The results revealed that the in vitro drug release of prepared formulations, F1, F2, F3, and F4 was subjected for acid resistance test for 2 h in 0.1N HCl and has a comparable dissolution profile in phosphate buffer of 6.8 pH. FormulationF4 was subjected for stability studies and no significant difference was observed in 3 mo 40 Â°C/75% RH accelerated stability condition.

Conclusion: The dissolution profile of formulation F4 was found better than that of market product. Based on evaluation results, the study concluded that F4formulationwas considered as an optimized formulation.

Â

Downloads

Download data is not yet available.

Author Biography

D. V. Gowda, Department of Pharmaceutics, JSS College of Pharmacy, Sri Shivarathreeshwara Nagara, Mysuru, JSS Academy of Higher Education and Research, JSS Medical Institutions Campus, Sri Shivarathreeshwara Nagara, Mysuru 570015, Karnataka, India

Professor

References

Hadi MA, Rao NR, Rao AS. Formulation and evaluation of pH-responsive mini-tablets for ileo-colonic targeted drug delivery. Trop J Pharm Res 2014;13:1021-9.

Mohd AH, Rao NG, Avanapu SR. Matrix-mini-tablets of lornoxicam for targeting early morning peak symptoms of rheumatoid arthritis. Iran J Basic Med Sci 2014;17:357.

Jeevana JB, Jyosna D. multi-particulate drug delivery systems using natural polymers as release retardant materials. Int J Pharm Pharm Sci 2010;6:61-5.

Ranjith K, Mahalaxmi R. Pharmaceutical mini tablets. Int J Pharmtech Res 2015;7:507-15.

Patel SA, Patel NG, Joshi AB. Multiple unit pellet system (mups) based fast disintegrating delayed-release tablets for pantoprazole delivery. Int J Pharm Pharm Sci 2010;10:77-84.

Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. Utilization of poly (DL-lactide-co-glycolide) nanoparticles for the preparation of mini-depot tablets by direct compression. J Controlled Release 2000;67:29-36.

List AF, Baker AF, Green S, Bellamy W. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. Cancer Control 2006;13:4-11.

Jacob S, Shirwaikar AA, Joseph A, Srinivasan KK. Novel co-processed excipients of mannitol and microcrystalline cellulose for preparing fast dissolving tablets of glipizide. Indian J Pharm Sci 2007;69:633.

Saettone MF, Chetoni P, Bianchi LM, Giannaccini B, Conte U, Sangalli ME. Controlled release of timolol maleate from coated ophthalmic mini-tablets prepared by compression. Int J Pharm 1995;126:79-82.

Kenneth N, Parthasarathy V, Narendra C, Kalyani P. Development and evaluation of oral controlled release matrix tablets of lamivudine optimization and in vitro-in vivo studies. Int J Pharm Pharm Sci 2015;7:95-101.

Vuong H, Palmer D, Levina M, Rajabi AR. Investigation of enteric coating of mini-tablets using a perforated pan or a fluid Bed machine. In: Poster Reprint Controlled Release Society Annual Meeting; 2008.

Li YH, Zhu JB. Modulation of combined-release behaviors from a novel tablets-in-capsule systemâ€. J Controlled Release 2004;95:381-9.

Gasthuys F, Pockele K, Vervaet C, Weyenberg W, De Prijck K, Pille F, et al. Evaluation of the in vivo behavior of gentamicin sulphate ocular miniâ€tablets in ponies. J Vet Pharmacol Ther 2007;30:470-6.

Rows RC, Sheskay PJ, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. Pharmaceutical Press; 2009. p. 2018.

Hiorth M, Nilsen S, Tho I. Bioadhesive mini-tablets for vaginal drug delivery. Int J Pharm 2014;6:494-511.

Nair AB, Gupta R, Kumria R, Jacob S, Attimarad M. Formulation and evaluation of enteric coated tablets of proton pump inhibitor. J Basic Clin Pharm 2010;1:215.

De Brabander C, Vervaet C, Fiermans L, Remon JP. Matrix mini-tablets based on starch/microcrystalline wax mixtures. Int J Pharm 2000;199:195-203.

Keerthi ML, Kiran RS, Rao VU, Sannapu A, Dutt AG, Krishna KS. Pharmaceutical mini-tablets, its advantages, formulation possibilities and general evaluation aspects: a review. Int J Pharm Sci Rev Res 2014;28:214-21.

Khatavkar U, Kumar K, Shimipi S. Novel approaches for the development of oral controlled release compositions of galantamine hydrobromide and paroxetine hydrochloride hemihydrate. Int J Appl Pharm 2016;8:1-6.